AR and metastatic prostate carcinoma: Beltran and coworkers have investigated a group of t-SCNC metastatic prostatic cancers and showed that RB1 loss was more frequent in t-SCNC (70%) than in Adeno (32%) CRPCs; TP53 was more frequently mutated in t-SCNC (66%) than in Adeno (31%) CRPC samples; AR point mutations were absent in t-SNCN samples and AR signaling is usually attenuated in these tumors [93].